{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graft+vs.+Host+Disease&page=7",
    "query": {
      "condition": "Graft vs. Host Disease",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 831,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graft+vs.+Host+Disease&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graft+vs.+Host+Disease&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T21:12:24.733Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00520130",
      "title": "Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Hodgkin's Lymphoma",
        "Non-Hodgkin's Disease",
        "Acute Leukemia",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Allogenic stem cell transplant (ASCT)",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "TMS",
          "type": "DRUG"
        },
        {
          "name": "FLAG",
          "type": "DRUG"
        },
        {
          "name": "EPOCH-F",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 92,
      "start_date": "2007-10-30",
      "completion_date": "2018-12-31",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00520130"
    },
    {
      "nct_id": "NCT00224055",
      "title": "Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia, Iron-Deficiency",
        "Kidney Failure, Chronic"
      ],
      "interventions": [
        {
          "name": "Sodium Ferric Gluconate Complex in Sucrose Injection",
          "type": "DRUG"
        },
        {
          "name": "Ferrous sulfate tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Watson Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2003-04",
      "completion_date": "2004-09",
      "has_results": true,
      "last_update_posted_date": "2012-03-29",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00224055"
    },
    {
      "nct_id": "NCT07124078",
      "title": "A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Graft-versus-host-disease"
      ],
      "interventions": [
        {
          "name": "INCA034176",
          "type": "DRUG"
        },
        {
          "name": "Best available Treatment (BAT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-05-20",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07124078"
    },
    {
      "nct_id": "NCT00822770",
      "title": "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stem Cell Transplantation",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic blood stem cell transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "ATG (Thymoglobulin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2009-01",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822770"
    },
    {
      "nct_id": "NCT01927120",
      "title": "In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft-Versus-Host-Disease"
      ],
      "interventions": [
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-03-25",
      "completion_date": "2017-03-09",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01927120"
    },
    {
      "nct_id": "NCT02204020",
      "title": "Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "5-azacytidine (5-aza) maintenance therapy after transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-04",
      "completion_date": "2016-05-04",
      "has_results": false,
      "last_update_posted_date": "2018-03-30",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204020"
    },
    {
      "nct_id": "NCT03112603",
      "title": "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft-versus-host Disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Extracorporeal photopheresis (ECP)",
          "type": "DRUG"
        },
        {
          "name": "Low-dose methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Pentostatin",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2017-06-29",
      "completion_date": "2022-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03112603"
    },
    {
      "nct_id": "NCT04543227",
      "title": "Opioid Laws and Pediatric Use",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Burns",
        "Knee Injuries",
        "Opioid Use",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Opioid Use 90-Days Post Treatment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 980,
      "start_date": "2020-09-10",
      "completion_date": "2023-11-16",
      "has_results": false,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04543227"
    },
    {
      "nct_id": "NCT03086551",
      "title": "Modulating Interaction of Motor Learning Networks in Rehabilitation of Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stroke",
        "Stroke, Chronic",
        "Stroke, Middle Cerebral Artery With Infarction"
      ],
      "interventions": [
        {
          "name": "Active continuous theta burst stimulation (cTBS)",
          "type": "DEVICE"
        },
        {
          "name": "Placebo (Sham) continuous theta burst stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Motor Practice",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-04-01",
      "completion_date": "2019-03-30",
      "has_results": true,
      "last_update_posted_date": "2020-04-27",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03086551"
    },
    {
      "nct_id": "NCT02176980",
      "title": "Hepatitis C Alcohol Reduction Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C, Chronic; AUD"
      ],
      "interventions": [
        {
          "name": "Brief alcohol counseling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Group and Individual Therapy Sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2014-10",
      "completion_date": "2018-09-30",
      "has_results": false,
      "last_update_posted_date": "2018-10-18",
      "last_synced_at": "2026-10-13T21:12:24.733Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176980"
    }
  ]
}